3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
1
Peripheral Nervous System Diseases
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
182
Magnetic Resonance Spectroscopy
161
Specimen Handling
134
enzalutamide
125
Nivolumab
118
Gemcitabine
96
Docetaxel
92
Radiosurgery
91
Prednisone
81
Androgen Antagonists
81
Abiraterone Acetate
79
Radiotherapy
75
apalutamide
66
Cisplatin
65
darolutamide
62
Ipilimumab
61
Biopsy
61
abiraterone
57
cabozantinib
55
Carboplatin
55
Leuprolide
52
enfortumab vedotin
50
Radiation
47
Pluvicto
45
Standard of Care
44
atezolizumab
41
Surveys and Questionnaires
38
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
37
X-Rays
37
avelumab
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Single Person
×
Genitourinary
×
1 year
×
Clear all
NCT07629700
2026-06-05
ENDEAVOR
University of Florence
Phase NA
Not yet recruiting
40 enrolled
NCT07260435
2025-12-03
Apa/Enza-short
Erasmus Medical Center
Phase 3
Recruiting
400 enrolled